arch pharmalabs limited unlisted shares
Enquiry
About Arch Pharmalabs Limited Unlisted Shares
ARCH PHARMALABS LIMITED, a Pharmaceutical Company aligned across two business verticals viz. Products and Services. Company’s Products business comprises manufacturing and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both Domestic and International markets including the regulated markets.
Company presently has 7 manufacturing facilities across India. All these 7 manufacturing facilities are multipurpose with reactor capacities of around 1000 KL plus.
Manufacturing facilities at:
- Gurgaon, Vitalife site
- Hyderabad, Merven Site
- Hyderabad, Watsol Site
- Mumbai, Badlapur Site
- Tarapur, Oncology Site
- Mumbai, Taloja Site
- Mumbai, Dombivli Site
Key managerial Person:
Ajit Kamath, 51, is the Executive Chairman and Managing Director of our Company, first appointed on January 1, 2001. He holds a Bachelor's Degree in Commerce from the University of Mumbai and has 19 years of experience in the pharmaceutical industry. Before joining our Company, he worked with CEAT Financial Services Limited and co-founded Arch Commerz Private Limited. He has played a key role in our Company's acquisitions, including the Gurgaon Unit in December 2004, and has been vital in business strategy and development.
Rajendra Kaimal, 48, is the Executive Director of our Company, first appointed on November 1, 2003. He holds a Bachelor's Degree in Commerce from the University of Mumbai, a Master's in Management Studies from Narsee Monjee Institute, and is a Cost Accountant. A co-founder of Arch Commerz Private Limited, he has 18 years of experience in the pharmaceutical industry. Rajendra oversees the Company's commercial operations, including purchase and export functions, and coordinates daily activities across all manufacturing facilities.
Equity Issuance to Nipro Pharmapackaging
On 8 March 2023, company issued 45,57,637 equity shares @ Rs. 328 per share to Nipro Pharmapackaging India Private Limited by way of non cash consideration i.e., by conversion of financial obligation.
| Price Per Equity Share | ₹ 85 |
| Lot Size | 250 Shares |
| 52 Week High | ₹ ** |
| 52 Week Low | ₹ ** |
| Depository | NSDL & CDSL |
| PAN Number | AACCM0306Q |
| ISIN Number | INE182F01017 |
| CIN | U24231MH1993PLC150891 |
| RTA | Link Intime |
| Market Cap (in cr.) | ₹ 1330.08 |
| P/E Ratio | 10.9 |
| P/B Ratio | 1.57 |
| Debt to Equity | 1.01 |
| ROE (%) | 14.57 |
| Book Value | 54.16 |
| Face Value | 10 |
| Total Shares | 156480000 |
Financials
| P&L Statement | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenue | 706 | 1309 | 1341 |
| Cost of Material Consumed | 444 | 1052 | 1062 |
| Gross Margins | 37.11 | 19.63 | 20.81 |
| Change in Inventory | 21 | -68 | -37 |
| Employee Benefit Expenses | 74 | 75 | 69 |
| Other Expenses | 892 | 73 | 67 |
| EBITDA | -725 | 177 | 180 |
| OPM | -102.69 | 13.52 | 13.42 |
| Other Income | 2853 | -1 | 1 |
| Finance Cost | 231 | 98 | 35 |
| D&A | 28 | 25 | 23 |
| EBIT | -753 | 152 | 157 |
| EBIT Margins | -106.66 | 11.61 | 11.71 |
| PBT | 1869 | 52 | 122 |
| PBT Margins | 264.73 | 3.97 | 9.1 |
| Tax | 0 | 0 | 0 |
| PAT | 1869 | 52 | 122 |
| NPM | 264.73 | 3.97 | 9.1 |
| EPS | 123.03 | 3.42 | 7.8 |
| Financial Ratios | 2021 | 2022 | 2023 |
|---|---|---|---|
| Operating Profit Margin | -102.69 | 13.52 | 13.42 |
| Net Profit Margin | 264.73 | 3.97 | 9.1 |
| Earning Per Share (Diluted) | 123.03 | 3.42 | 7.8 |